These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 15606458)

  • 1. Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration.
    Frennesson CI; Nilsson SE
    Acta Ophthalmol Scand; 2004 Dec; 82(6):645-50. PubMed ID: 15606458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.
    Bressler NM; Arnold J; Benchaboune M; Blumenkranz MS; Fish GE; Gragoudas ES; Lewis H; Schmidt-Erfurth U; Slakter JS; Bressler SB; Manos K; Hao Y; Hayes L; Koester J; Reaves A; Strong HA;
    Arch Ophthalmol; 2002 Nov; 120(11):1443-54. PubMed ID: 12427056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy with verteporfin in patients with age-related macular degeneration and juxtafoveal choroidal neovascularization.
    Frennesson CI
    Acta Ophthalmol Scand; 2004 Dec; 82(6):651-5. PubMed ID: 15606459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
    Pieramici DJ; Bressler SB; Koester JM; Bressler NM
    Arch Ophthalmol; 2006 May; 124(5):660-4. PubMed ID: 16682587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
    Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
    Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.
    Verteporfin Roundtable Participants
    Retina; 2005; 25(2):119-34. PubMed ID: 15689800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital.
    Essex RW; Qureshi SH; Cain MS; Harper CA; Guymer RH
    Clin Exp Ophthalmol; 2003 Dec; 31(6):476-81. PubMed ID: 14641153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
    Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
    Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.
    Incorvaia C; Campa C; Parmeggiani F; Menzione M; D'Angelo S; Della Corte M; Rinaldi M; Romano M; Dell'omo R; Costagliola C
    Retina; 2008 Feb; 28(2):289-97. PubMed ID: 18301052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes.
    ; ;
    Retina; 2002 Feb; 22(1):6-18. PubMed ID: 11884872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.
    Kaiser PK;
    Graefes Arch Clin Exp Ophthalmol; 2006 Sep; 244(9):1132-42. PubMed ID: 16538452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2.
    Barbazetto I; Burdan A; Bressler NM; Bressler SB; Haynes L; Kapetanios AD; Lukas J; Olsen K; Potter M; Reaves A; Rosenfeld P; Schachat AP; Strong HA; Wenkstern A; ;
    Arch Ophthalmol; 2003 Sep; 121(9):1253-68. PubMed ID: 12963608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration.
    Michels S; Wachtlin J; Gamulescu MA; Heimann H; Prünte C; Inhoffen W; Krebs I; Schmidt-Erfurth U
    Ophthalmology; 2005 Dec; 112(12):2070-5. PubMed ID: 16225928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD.
    Hamon F; Goeminne P
    Semin Ophthalmol; 2001 Dec; 16(4):223-32. PubMed ID: 15513445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.
    Arias L; Garcia-Arumi J; Ramon JM; Badia M; Rubio M; Pujol O
    Ophthalmology; 2006 Dec; 113(12):2243-50. PubMed ID: 16996600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
    Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.